GlassScriptPhysician profile
William Meek
NPI 1639518301
$2,906.86
in general payments reported to CMS, 2019-2025
24 companies · $1,590 in 2025
The $1,590 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $301 · 2023: $12.70 · 2024: $1,003 · 2025: $1,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,542 · Education: $63.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,542.22 |
| Education | $63.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $443.73 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Novo Nordisk INC | $388.36 | 2024-2025 | Wegovy, Ozempic |
| Novartis Pharmaceuticals Corporation | $312.57 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $206.73 | 2024-2025 | Verquvo, Winrevair, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $180.30 | 2023-2025 | Lokelma, Farxiga |
| Pfizer INC. | $179.74 | 2024-2025 | |
| Lilly USA, LLC | $167.40 | 2021-2025 | Zepbound |
| Biohaven Pharmaceuticals, INC. | $143.72 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.29 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $112.07 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.57 | 2021-2025 | Jardiance |
| Amgen INC. | $83.58 | 2024-2025 | Repatha, Repatha |
| Lexicon Pharmaceuticals, INC. | $83.55 | 2024 | |
| Janssen Pharmaceuticals, INC | $78.68 | 2024 | Xarelto |
| Esperion Therapeutics, INC. | $75.67 | 2024-2025 | Nexletol |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.85 | 2025 | Lifevest |
| Scpharmaceuticals INC. | $37.06 | 2025 | |
| Bridgebio Pharma, INC. | $22.97 | 2025 | Attruby |
| Vital Connect, INC | $20.76 | 2024 | Vitalpatch Rtm |
| Paratek Pharmaceuticals, INC. | $19.96 | 2021 | |
| Glaxosmithkline, LLC. | $17.53 | 2025 | Arexvy, Shingrix |
| Abbvie INC. | $15.22 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Meek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.